Recce Ltd. | Balance Sheet

Fiscal year is July-June. All values AUD Thousands.
2015
2016
2017
2018
Cash & Short Term Investments
451.70
3,591.40
1,090.40
679.70
Total Accounts Receivable
15.80
39.60
60.20
21
Other Current Assets
-
6.40
3.40
7.80
Total Current Assets
467.50
3,637.40
1,154.00
708.50
Net Property, Plant & Equipment
78.90
83.30
310.60
435.20
Total Assets
546.40
3,720.70
1,464.60
1,143.70
ST Debt & Current Portion LT Debt
-
7.00
-
Accounts Payable
239.00
18.80
255.40
Other Current Liabilities
26.80
169.30
434.90
Total Current Liabilities
265.80
195.10
690.30
Long-Term Debt
-
-
161.30
Provision for Risks & Charges
6.70
11.70
22.90
Total Liabilities
272.50
206.80
874.40
Common Equity (Total)
274.00
3,513.90
590.10
Total Shareholders' Equity
274.00
3,513.90
590.10
Total Equity
274.00
3,513.90
590.10
Liabilities & Shareholders' Equity
546.40
3,720.70
1,464.60

About Recce

View Profile
Address
Gateway Tower
Sydney Western Australia (WA) 2000
Australia
Employees -
Website http://www.recce.com.au
Updated 07/08/2019
Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. It produces antibiotics that are effective in attacking disease-causing Gram-positive and Gram-negative bacteria. The company was founded on April 11, 2007 and is headquartered in Bentley, Australia.